



Meda expands Axorid collaboration

Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

Axorid consists of the well-known and broadly used substances; *ketoprofen*, a NSAID (Non Steroidal Anti-Inflammatory Drug) for the treatment of rheumatic disorders, and *omeprazole*, an acid reducing proton pump inhibitor (PPI). Axorid can prevent gastrointestinal side effects from use of NSAIDs. Axorid's once-daily administration can also increase patient compliance.

If questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in more than 40 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.